With the continuous advancement of the internationalization process, China has also implemented some incentives for enterprises to develop the internationalization of their preparations. Compared with multinational companies, Chinese local companies account for a relatively low proportion of developed pharmaceutical markets such as Europe, the United States, Japan and other countries. However, as more and more companies have passed the European and American certifications, they are increasingly exporting drugs to developed markets such as the United States, the United Kingdom, and the Netherlands. increase.
According to statistics, in 2013, China exported 175 Western medicines to 173 countries and regions. Australia, the European Union, South Korea, and the United States are still the major markets for the export of western medicines in China, accounting for 47.9% of China’s total exports of pharmaceutical preparations, but the status of the EU and the United States. It has been significantly weakened and dropped to the second and fourth place respectively. This is mainly due to the improvement of the construction of the bonded area in China and the rapid development of the warehousing and logistics industry, which has enabled the rapid development of the warehousing and re-export trade in the bonded area, and it has become a transnational corporation to Australia, South Korea, etc. Delivery of medicines provides convenience.
In 2013, China exported 120 million U.S. dollars worth of western medicines to the United States, a year-on-year increase of 14.3%. This was particularly marked by the pull of local companies. Zhejiang Kangle, Huahai, Nantong All Asia, Shandong Xinhua, Jiangsu Jiangshan, etc., all achieved substantial exports to the United States. Growth, while foreign companies such as Pfizer China and Eye Lijian had a significant decline in their exports of US preparations.
Although AstraZeneca, Novo Nordisk, Pfizer, Huarui, GSK, etc. are still the main exporters in the EU's formulation exports, the growth of China's domestic companies is also very significant. Huahai Pharmaceutical, Shenzhen Lijian, Anhui Huaan, Stone drug, Shandong Xinhua, and other enterprises that have passed the EU certification have increased by more than 50%. Shanghai Rongheng wins through channels.
In the process of steadily advancing the export of pharmaceuticals in developed markets, many companies have turned their attention to emerging markets with an average annual growth rate of 13% to 16%. In 2013, China’s exports to ASEAN, Africa, and Latin America achieved rapid growth, with growth rates of 29.7%, 18.9%, and 9.8%, respectively. Africa, Nigeria, Kenya, Sudan, Democratic Republic of the Congo, Guinea, and Angola were the most important markets. The annual export volume is more than 20 million US dollars, and the majority increase is more than 25%. Malaysia, the Philippines, Vietnam, Thailand, and Myanmar are the top five markets for China's exports of pharmaceutical preparations to ASEAN, accounting for 79% of the total, with annual exports exceeding US$27 million. In spite of this, the share of China's preparations in ASEAN's imports is still relatively low, accounting for only about 5%, but there is an increasing trend. In contrast, China’s exports to South America continue to be concentrated in several countries in Peru, Colombia, and Venezuela, and most of them have entered through tendering, and the growth rate in 2013 was large.
It is worth noting that Chinese enterprises have accelerated the development of pharmaceutical markets in Russia and the surrounding areas. In 2013, China’s exports to Uzbekistan, Kazakhstan, Kyrgyzstan, and other countries all achieved an increase of more than 15%.
In recent years, China has also implemented a number of policies and financial support to encourage companies to develop the internationalization of pharmaceutical preparations, provide industrial transformation and upgrading, and a large number of enterprises such as Huahai, Hisun, and Jingxin Pharmaceutical have also received financial support from the country to varying degrees. However, it is undeniable that there are still varying degrees of problems in the field of commissioned processing, foreign registration, and export supervision in the field of pharmaceutical preparations. It is necessary for the government, industry, and the enterprise to jointly promote the development of the foreign trade of pharmaceutical preparations.
According to statistics, in 2013, China exported 175 Western medicines to 173 countries and regions. Australia, the European Union, South Korea, and the United States are still the major markets for the export of western medicines in China, accounting for 47.9% of China’s total exports of pharmaceutical preparations, but the status of the EU and the United States. It has been significantly weakened and dropped to the second and fourth place respectively. This is mainly due to the improvement of the construction of the bonded area in China and the rapid development of the warehousing and logistics industry, which has enabled the rapid development of the warehousing and re-export trade in the bonded area, and it has become a transnational corporation to Australia, South Korea, etc. Delivery of medicines provides convenience.
In 2013, China exported 120 million U.S. dollars worth of western medicines to the United States, a year-on-year increase of 14.3%. This was particularly marked by the pull of local companies. Zhejiang Kangle, Huahai, Nantong All Asia, Shandong Xinhua, Jiangsu Jiangshan, etc., all achieved substantial exports to the United States. Growth, while foreign companies such as Pfizer China and Eye Lijian had a significant decline in their exports of US preparations.
Although AstraZeneca, Novo Nordisk, Pfizer, Huarui, GSK, etc. are still the main exporters in the EU's formulation exports, the growth of China's domestic companies is also very significant. Huahai Pharmaceutical, Shenzhen Lijian, Anhui Huaan, Stone drug, Shandong Xinhua, and other enterprises that have passed the EU certification have increased by more than 50%. Shanghai Rongheng wins through channels.
In the process of steadily advancing the export of pharmaceuticals in developed markets, many companies have turned their attention to emerging markets with an average annual growth rate of 13% to 16%. In 2013, China’s exports to ASEAN, Africa, and Latin America achieved rapid growth, with growth rates of 29.7%, 18.9%, and 9.8%, respectively. Africa, Nigeria, Kenya, Sudan, Democratic Republic of the Congo, Guinea, and Angola were the most important markets. The annual export volume is more than 20 million US dollars, and the majority increase is more than 25%. Malaysia, the Philippines, Vietnam, Thailand, and Myanmar are the top five markets for China's exports of pharmaceutical preparations to ASEAN, accounting for 79% of the total, with annual exports exceeding US$27 million. In spite of this, the share of China's preparations in ASEAN's imports is still relatively low, accounting for only about 5%, but there is an increasing trend. In contrast, China’s exports to South America continue to be concentrated in several countries in Peru, Colombia, and Venezuela, and most of them have entered through tendering, and the growth rate in 2013 was large.
It is worth noting that Chinese enterprises have accelerated the development of pharmaceutical markets in Russia and the surrounding areas. In 2013, China’s exports to Uzbekistan, Kazakhstan, Kyrgyzstan, and other countries all achieved an increase of more than 15%.
In recent years, China has also implemented a number of policies and financial support to encourage companies to develop the internationalization of pharmaceutical preparations, provide industrial transformation and upgrading, and a large number of enterprises such as Huahai, Hisun, and Jingxin Pharmaceutical have also received financial support from the country to varying degrees. However, it is undeniable that there are still varying degrees of problems in the field of commissioned processing, foreign registration, and export supervision in the field of pharmaceutical preparations. It is necessary for the government, industry, and the enterprise to jointly promote the development of the foreign trade of pharmaceutical preparations.
Product categories of Hydraulic Hose, we are specialized manufacturers from China, Hydraulic Hose, Spiral Reinforced Hydraulic Hose suppliers/factory, wholesale high-quality products of Six-Steel Spiraled Hydraulic Hose R & D and manufacturing, we have the perfect after-sales service and technical support. Look forward to your cooperation!
Hydraulic Hose,Spiral Reinforced Hydraulic Hose,Six-Steel Spiraled Hydraulic Hose,Resin Twin Hose
SHIJIAZHUANG STRONGFLEX I/E CO.,LTD. , https://www.sjzhydraulichose.com